Brexit and COVID-19: Changes to the Regulation of Medicines

By , and on April 28, 2021

The combination of the Coronavirus (COVID-19) pandemic and the imminent end of the Brexit transition period means a fast-changing regulatory environment for medicines.

In October 2020, the UK Government made changes to the regulation of medicines for COVID-19 and influenza. The regulations set out changes for the temporary authorisation of medicines (including COVID-19 vaccines) and allow the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to set conditions for that authorisation.

Access the article.

Sharon Lamb
Sharon Lamb focuses her practice on transactional and regulatory advice in the health and life sciences sector. She advises on global transactional mandates, including mergers and acquisitions and joint ventures in health services, pharma and life sciences, digital health and health data technologies. Read Sharon Lamb's full bio.

Gary Howes

Bella North




Top ranked chambers 2022
US leading firm 2022